Adjuvant therapy of histopathological risk factors of retinoblastoma in Europe: A survey by the European Retinoblastoma Group (EURbG).
Sabine Dittner-MoormannMadlen ReschkeFloor C H AbbinkIsabelle AertsHatice Tuba AtalayNadezhda Fedorovna BobrovaEva BiewaldInes B BrechtShani CaspiNathalie CassouxGuilherme CastelaYelena DiarraCatriona DuncanMartin EbingerDavid Garcia AldanaDoris HadjistilianouTomáš KepákArtur KlettHayyam KiratliErika MakaEnrico OpocherKatarzyna Pawinska-WasikowskaJelena RasconIda RussoOlga Rutynowska-PronickaConstantino Sábado ÁlvarezSonsoles San Roman PachecoKarel SvojgrBeate TimmermannVicktoria Vishnevskia-DaiAngelika EggertPetra Ritter-SovinzNikolaos E BechrakisHelen JenkinsonAnnette MollFrancis L MunierMaja Beck PopovicGuillermo L ChantadaFrançois DozPetra KettelerPublished in: Pediatric blood & cancer (2021)
Indications and adjuvant treatment regimens in European retinoblastoma referral centres are similar but not uniform. Further biomarkers in addition to histopathological risk factors could improve treatment stratification. The high consensus in European centres is an excellent foundation for a common European study with prospective validation of new biomarkers.